Autres langues Johnson & Johnson

Actions

JNJ

US4781601046

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:02 08/05/2026			Varia. 5j.	Varia. 1 janv.
221,32 ^USD	-0,53 %		-2,58 %	+6,94 %

09/05	La réussite fiscale irlandaise face au risque de dépendance
07/05	Johnson & Johnson lance 'Generation Fine', un nouveau mouvement incitant les patients à accroître leurs attentes envers les traitements contre la dépression et à viser la rémission	RE

Autres langues

09/05	Ireland's fiscal success faces the risk of over-reliance
07/05	Johnson & Johnson launches "Generation Fine," a new movement encouraging patients to expect more from depression treatment and aim for remission
07/05	Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
07/05	Breach Of Contract, IP Rights, And Irreparable Harm: Lessons From The Third Circuit’s Stelara Decision
06/05	Bayer's experimental blood thinner cuts risk and severity of repeat strokes
05/05	CVS to drop J&J's Stelara from its main formularies
05/05	Johnson & Johnson : study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
05/05	Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
05/05	Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
05/05	Johnson & Johnson Announces Phase 2b Data For JNJ-4804 Co-Antibody Therapy In Refractory Inflammatory Bowel Disease
05/05	Johnson & Johnson Announces Positive Phase 3 Fuzion Study Results For Tremfya In Perianal Fistulizing Crohn?s Disease
05/05	Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
05/05	Johnson & Johnson Announces Pivotal Clinical Study Results for A New Soft-Tissue Surgical Robotic System
05/05	Nanobiotix Flags US FDA's Acceptance of Protocol Amendment for Head, Neck Cancer Study
04/05	Johnson & Johnson : Promising Data from US Pilot Study Shows Planned Impella 5.5 Use is Safe and Feasible in Non-Shock, High-Risk Cardiac Surgery Patients
04/05	Global pharma companies that have publicly announced Trump drug pricing agreements
04/05	Caplyta® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive mdd treatments in new network meta-analysis
04/05	CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
04/05	Kyverna Therapeutics, Inc. Appoints Nadia Dac as Chief Commercial Officer, Effective May 4, 2026
04/05	Johnson & Johnson Shows Greatest Improvement Across Key Efficacy Outcomes for Caplyta (Lumateperone) Among Adjunctive Mdd Treatments in New Network Meta-Analysis
04/05	Johnson & Johnson : to Present New Data Spanning Vision Portfolio at ARVO 2026
02/05	Johnson and Johnson Innovative Medicine Announces Stelara Pediatric Crohn's Disease Fda Approval
01/05	Johnson & Johnson : STELARA® Pediatric Crohn’s Disease FDA Approval J&J Statement
01/05	Johnson & Johnson statement on investigational programs in large B-cell lymphoma
30/04	Stryker misses quarterly estimates on muted demand for medical devices